Evolus, which is preparing to launch a biosimilar version of Botox, raised $60 million by offering 5 million shares at $12, the low end of the range of $12 to $14. Evolus plans to list on the Nasdaq under the symbol EOLS. Cantor Fitzgerald and Mizuho Securities acted as lead managers on the deal.
